KalVista Pharmaceuticals Has Initiated Open-Label KONFIDENT-KID Trial Of Sebetralstat In Pediatric Patients With Hereditary Angioedema. The Trial Will Enroll Approximately 24 Children Aged 2 To 11 Years
Portfolio Pulse from Benzinga Newsdesk
KalVista Pharmaceuticals has initiated the KONFIDENT-KID trial of sebetralstat in pediatric patients with hereditary angioedema. The trial will enroll approximately 24 children aged 2 to 11 years. If approved, sebetralstat would be the first oral on-demand therapy for this age group and the second FDA-approved on-demand therapy of any type in this population.
June 27, 2024 | 10:37 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
KalVista Pharmaceuticals has initiated a trial for sebetralstat in pediatric patients with hereditary angioedema. If successful, this could lead to the first oral on-demand therapy for children aged 2-11, significantly expanding the market for sebetralstat.
The initiation of the KONFIDENT-KID trial is a significant step for KalVista Pharmaceuticals. If sebetralstat is approved, it will be the first oral on-demand therapy for pediatric patients aged 2-11 with hereditary angioedema, potentially leading to increased market share and revenue for the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100